As Microsoft (MSFT) Share Value Rose, Haverford Financial Services Boosted by $5.93 Million Its Holding; Greylin Investment Mangement Cut Stake in Teva Pharmaceutical Inds LTD (TEVA) as Share Price Declined

February 21, 2018 - By Stephen Andrade

Greylin Investment Mangement Inc decreased its stake in Teva Pharmaceutical Inds Ltd (TEVA) by 21.95% based on its latest 2017Q3 regulatory filing with the SEC. Greylin Investment Mangement Inc sold 64,630 shares as the company’s stock declined 15.11% while stock markets rallied. The institutional investor held 229,865 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $4.05 million, down from 294,495 at the end of the previous reported quarter. Greylin Investment Mangement Inc who had been investing in Teva Pharmaceutical Inds Ltd for a number of months, seems to be less bullish one the $20.32 billion market cap company. The stock decreased 4.40% or $0.92 during the last trading session, reaching $19.98. About 17.82M shares traded. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has declined 41.70% since February 21, 2017 and is downtrending. It has underperformed by 58.40% the S&P500.

Haverford Financial Services Inc increased its stake in Microsoft Corp (MSFT) by 995.79% based on its latest 2017Q3 regulatory filing with the SEC. Haverford Financial Services Inc bought 80,191 shares as the company’s stock rose 4.75% with the market. The institutional investor held 88,244 shares of the prepackaged software company at the end of 2017Q3, valued at $6.57 million, up from 8,053 at the end of the previous reported quarter. Haverford Financial Services Inc who had been investing in Microsoft Corp for a number of months, seems to be bullish on the $713.93 billion market cap company. The stock increased 0.78% or $0.72 during the last trading session, reaching $92.72. About 30.91 million shares traded or 7.72% up from the average. Microsoft Corporation (NASDAQ:MSFT) has risen 34.52% since February 21, 2017 and is uptrending. It has outperformed by 17.82% the S&P500.

Since August 29, 2017, it had 0 insider buys, and 2 selling transactions for $5.98 million activity. COURTOIS JEAN PHILIPPE had sold 26,763 shares worth $1.98M.

Among 37 analysts covering Microsoft Corporation (NASDAQ:MSFT), 29 have Buy rating, 2 Sell and 6 Hold. Therefore 78% are positive. Microsoft Corporation had 167 analyst reports since July 22, 2015 according to SRatingsIntel. The stock has “Overweight” rating by Piper Jaffray on Thursday, December 22. J.P. Morgan maintained it with “Hold” rating and $87.0 target in Thursday, January 25 report. Wunderlich maintained Microsoft Corporation (NASDAQ:MSFT) rating on Wednesday, July 20. Wunderlich has “Hold” rating and $60 target. The stock of Microsoft Corporation (NASDAQ:MSFT) earned “Buy” rating by Canaccord Genuity on Thursday, October 5. Nomura maintained the shares of MSFT in report on Friday, February 2 with “Buy” rating. As per Friday, January 27, the company rating was maintained by Canaccord Genuity. Jefferies maintained it with “Sell” rating and $49.0 target in Thursday, October 26 report. On Friday, August 28 the stock rating was maintained by Global Equities Research with “Overweight”. The firm earned “Outperform” rating on Thursday, March 17 by Oppenheimer. The stock of Microsoft Corporation (NASDAQ:MSFT) has “Buy” rating given on Wednesday, September 27 by Bernstein.

Investors sentiment increased to 0.83 in Q3 2017. Its up 0.01, from 0.82 in 2017Q2. It improved, as 40 investors sold MSFT shares while 952 reduced holdings. 114 funds opened positions while 708 raised stakes. 5.51 billion shares or 0.32% less from 5.53 billion shares in 2017Q2 were reported. Hayek Kallen Invest Mngmt, Alabama-based fund reported 96,021 shares. Northrock Ltd Liability Com reported 14,267 shares or 0.4% of all its holdings. 6,220 are owned by Evermay Wealth Limited Com. Cypress Capital Mgmt Limited holds 173,329 shares. D Scott Neal has invested 0.08% in Microsoft Corporation (NASDAQ:MSFT). Somerset Gru Limited Liability has 27,706 shares for 1.88% of their portfolio. Grantham Mayo Van Otterloo Co Limited holds 4.58% or 10.52M shares. Poplar Forest Cap Ltd Liability Com owns 213,617 shares or 1.38% of their US portfolio. Colonial Trust holds 182,347 shares or 2.98% of its portfolio. Blue Chip Prns reported 144,618 shares stake. Hbk Investments Ltd Partnership has 202,100 shares. Rothschild Investment Il invested in 148,924 shares. Olstein Capital Lp holds 1.06% in Microsoft Corporation (NASDAQ:MSFT) or 110,000 shares. Zevenbergen Invests Lc holds 21,650 shares or 0.07% of its portfolio. Moreover, Manufacturers Life Insur The has 1.22% invested in Microsoft Corporation (NASDAQ:MSFT) for 13.78 million shares.

Greylin Investment Mangement Inc, which manages about $435.83M and $436.72M US Long portfolio, upped its stake in Bed Bath & Beyond Inc (NASDAQ:BBBY) by 108,730 shares to 214,215 shares, valued at $5.03 million in 2017Q3, according to the filing. It also increased its holding in Qualcomm Inc (NASDAQ:QCOM) by 26,695 shares in the quarter, for a total of 155,350 shares, and has risen its stake in Greenhill & Co Inc (NYSE:GHL).

Among 35 analysts covering Teva Pharma (NYSE:TEVA), 9 have Buy rating, 8 Sell and 18 Hold. Therefore 26% are positive. Teva Pharma had 146 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Neutral” rating given on Thursday, January 18 by BTIG Research. The rating was downgraded by Morgan Stanley on Wednesday, November 16 to “Equal-Weight”. The firm has “Buy” rating given on Monday, July 27 by Maxim Group. The rating was upgraded by Citigroup to “Buy” on Thursday, January 4. The stock has “Neutral” rating by Mizuho on Friday, February 10. Piper Jaffray maintained the stock with “Hold” rating in Friday, October 6 report. Cowen & Co maintained the shares of TEVA in report on Wednesday, April 5 with “Outperform” rating. The rating was downgraded by J.P. Morgan to “Sell” on Monday, November 13. The firm has “Hold” rating by Cantor Fitzgerald given on Thursday, June 22. The rating was maintained by Barclays Capital on Monday, August 7 with “Equal-Weight”.

Analysts await Teva Pharmaceutical Industries Limited (NYSE:TEVA) to report earnings on May, 10. They expect $0.64 earnings per share, down 37.86% or $0.39 from last year’s $1.03 per share. TEVA’s profit will be $650.79 million for 7.80 P/E if the $0.64 EPS becomes a reality. After $0.91 actual earnings per share reported by Teva Pharmaceutical Industries Limited for the previous quarter, Wall Street now forecasts -29.67% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts